



GRI Bio, Inc.

Reports Q4 results. We believe positive clinical data in Q2/Q3 2025 to be strong catalysts for stock. Lowering P/T to \$40.

COMPANY UPDATE

Rating: **BUY**

Ticker: GRI

Price: \$1.51

Target: \$40
(from \$221)

Reports Q4 results: GRI Bio recently (on March 17) reported its fiscal Q4 2024 (ending December) results. Net loss was \$3.9 million or EPS of \$(7.72), which compared with our estimates of \$(4.08) and consensus of \$(5.44). There was no Q4 guidance. GRI Bio is a clinical stage drug development company so it generates no revenue.

No guidance: Management did not provide forward guidance, but we believe ~\$2 million to be a reasonable near term quarterly cash burn rate.

Adjusting estimates: We are adjusting our 2025 estimates for EPS to \$(5.15) from \$(16.15).

Focus on immune response regulations: GRI Bio's science is founded on the discovery that NKT (Natural killer T) cells and dysregulated (uncontrolled) immune responses can be reset by regulating the activity of NKT cells to potentially treat a broad array of acute and chronic conditions.

GRI-0621: The company's initial main focus is developing GRI-0621 for the treatment of IPF (Idiopathic Pulmonary Fibrosis). GRI-0621 is designed to reset the dysfunctional immune response driving disease by inhibiting the activity of iNKT cells, as opposed to targeting a symptom of the disease.

Phase 2a Trial for GRI-0621: In December 2023, the company commenced enrollment for its GRI-0621 Phase 2a Trial in Patients with IPF. This trial will be a twelve-week, multicenter, multinational, randomized, placebo-controlled trial in approximately 36 patients with IPF. This trial is expected to take about one year.

Key data expected in Q2 2025 and Q3 2025: The company expects interim data from the Phase 2a study in Q2 2025 and top-line data in Q3 2025.

GRI-0803: The company's second planned drug product is GRI-0803, which is a novel oral agonist (activates a receptor to produce a biological response) of type 2 Natural Killer T (type 2 NKT) cells. The company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in SLE (systemic lupus erythematosus or lupus) and MS (multiple sclerosis).

IND for GRI-0803 in 2025: The company expects to file an IND (Investigational New Drug Application) for GRI-0803 to treat Lupus in 2025.

Large market potential for IPF: Idiopathic pulmonary fibrosis is one of the most common and severe form of progressive PF. IPF is on the rise with more than 40,000 new cases diagnosed annually. More than 250,000 Americans are living with PF and ILD, of which IPF affects approximately 140,000 patients in the U.S.

Large market potential for Lupus: The Lupus Foundation of America estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus. As many as 24,000 people in the U.S. are diagnosed with the disease each year.

Balance sheet: In Q4, GRI had \$5 million in cash and no debt. In the current Q2, the company raised \$5 million. We believe it has enough cash into 2026.

Positive high risks versus high rewards: Overall, concerns outweighed by growth prospects and valuation. GRI Bio's 2 drugs still have long development and commercialization roads left and the high risks of clinical trials or commercial failures, but we believe the ~billion dollars market potential presents high rewards for the risks.

Current valuation attractive: We are maintaining our BUY rating, but lowering our 12-month price target to \$40 from \$221, based on a NPV analysis, representing significant upside from the current share price. We believe this valuation fairly balances out the high risks with large upside opportunities.

Company Description

Based in La Jolla, CA, GRI Bio is a clinical-stage biopharmaceutical company focused on diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders.

United States
Healthcare

April 18, 2025

Edward Woo, CFA
(561) 327-9435
ewoo@ascendant.com

Stock Data

Exchange:	NasdaqCM
52-week Range:	1.10 – 117.13
Shares Outstanding (million):	2
Market cap (\$million):	\$3
EV (\$million):	\$(2)
Debt (\$million):	\$0
Cash (\$million):	\$5
Avg. Daily Trading Vol. (\$million):	\$1
Float (million shares):	1
Short Interest (million shares):	0.1
Dividend, annual (yield):	\$0 (NA%)

Revenues (US\$ million)

	<u>2025E</u> (Cur.)	<u>2025E</u> (Old)	<u>2026E</u> (Cur.)	<u>2026E</u> (Old)
Q1 Mar	0E		0E	
Q2 Jun	0E		0E	
Q3 Sep	0E		0E	
Q4 Dec	<u>0E</u>		<u>0E</u>	
Total	<u>0E</u>		<u>0E</u>	
EV/Revs	N/A		N/A	

Earnings per Share (pro forma)

	<u>2025E</u> (Cur.)	<u>2025E</u> (Old)	<u>2026E</u> (Cur.)	<u>2026E</u> (Old)
Q1 Mar	(4.11)E	(4.08)E	(0.96)E	
Q2 Jun	(1.10)E	(4.08)E	(0.92)E	
Q3 Sep	(1.05)E	(4.08)E	(0.88)E	
Q4 Dec	<u>(1.00)E</u>	<u>(3.91)E</u>	<u>(0.85)E</u>	
Total	<u>(5.15)E</u>	<u>(16.15)</u>	<u>(3.59)E</u>	
		E		
P/E	N/A		N/A	

*Reflects a 1:7 reverse stock split in January 2024.

*Reflects a 1:13 reverse stock split in June 2024.

*Reflects a 1:17 reverse stock split in February 2025.

Important Disclosures

Ascendant Capital Markets LLC seeks to do business with companies covered by its research team. Consequently, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making an investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report, beginning on page 21.

Exhibit 1: GRI Bio, Inc. Corporate Overview



A New Approach to Inflammatory Diseases

Summary

Elevating Clinical Stage Biotechnology
Company Advancing Innovative Pipeline
Across Multiple Orphan and High-Value
Inflammatory, Fibrotic and Autoimmune
Diseases

**We Believe NKT Science is Compelling
to Fundamental Institutional Investors
and Big Pharma Partners**

NKT Science

Leading NKT regulation
technology targeting earlier in
the inflammatory cascade to
interrupt disease progression

High-Value Indications

Clinical pipeline in potential high-
value indications with multiple
pipeline expansion opportunities

Proven Team

Team with proven NKT,
immunology and drug
development experience

Source: Company reports.

Exhibit 2: GRI Bio Investment Highlights

Highlights

Advancing an Innovative Pipeline of NKT Cell Modulators for the Treatment of Inflammatory, Fibrotic and Autoimmune Diseases

NKT Science	Innovative Small Molecules	High-Value Indications
Leveraging Natural Killer T (NKT) regulation to target earlier in the inflammatory cascade to interrupt disease progression	Small molecule drugs that act like cell therapy Provides favorable economics in manufacturing and dosing	~100K People in the US ¹ Idiopathic Pulmonary Fibrosis ~160K People in the US ² Systemic Lupus Erythematosus

Encouraging Preclinical Data Observed to Date on Par with OFEV® (nintedanib), a Leading Tyrosine Kinase Inhibitor with 2025 Projected Sales of \$5 Billion³

Source: Company reports.

Exhibit 3: GRI Bio Pipeline Expansion Opportunities

Pipeline Expansion Opportunities


Type 2 NKT Agonists For Autoimmunity

Potential Future Indications and Patient Populations (United States)



Source: Company reports.

Exhibit 4: GRI Bio Drug Pipeline Overview



Source: Company reports.


Exhibit 5: NKT Science

NKT SCIENCE:


Target the Immune Response Earlier in the Inflammatory Cascade to Interrupt Disease Progression

NKT Cells for Immune Regulation

Novel Immune Mechanism to Regulate the Adaptive-Innate Immune Axis & Reset Dysfunctional Immune Responses




Regulating NKT Cells is a Selective Approach to Immunomodulation via Resetting the Immune Response




Source: Company reports.

Exhibit 6: iNKT Cells Role in Inflammation



Source: Company reports.

Exhibit 7: Targeting iNKT Cells Upstream



Source: Company reports.

Exhibit 8: Good (Acute) vs. Bad (Chronic) Inflammation

TYPES OF INFLAMMATION

ACUTE "GOOD" INFLAMMATION



A serious threat triggers inflammation (a cut, bruise, infection, etc.)



The body releases inflammatory compounds



The job gets done & anti-inflammatory compounds are released. The body goes back to business as usual

CHRONIC "BAD" INFLAMMATION



A non-serious event triggers inflammation (eating a certain food, acne bacteria, etc.)




The body releases inflammatory compounds



The body *doesn't* release anti-inflammatory compounds and keeps sending an inflammatory response

GoodGlow.co

Acute Vs. Chronic Inflammation



Source: Inside Out Health Wellness

Source: GoodGlow.co and Inside Out Health Wellness.

Exhibit 9: GRI-0621 For Idiopathic Pulmonary Fibrosis (IPF) (as of 2024)

GRI-0621

Idiopathic Pulmonary Fibrosis (IPF)

Ongoing Phase 2a biomarker study with interim data expected Q1 2025 and topline data Q2 2025

Leveraging FDA agreed 505(b)(2) regulatory pathway

Orphan indication with ~40K newly diagnosed cases annually¹


GRI-0621 is a small molecule RAR- $\beta\gamma$ dual agonist that inhibits the activity of human iNKT cells. GRI-0621 has been shown to reduce aminotransferases and other LFTs in patients and improve fibrosis in multiple disease models. GRI is repurposing GRI-0621 as a once-daily oral capsule for the treatment of IPF with the potential to expand into additional fibrotic indications.

Key Highlights:

- Targets upstream in the inflammatory cascade providing potential for greater efficacy
- Favorable safety profile demonstrated in prior late stage studies
- iNKT inhibition demonstrated fibrosis resolution in multiple animal models
- Extensive IP protection with issued medical use patents and market LOE through 2036

Source: Company reports.

Exhibit 10: GRI-0621 Targets iNKT To Restore Homeostasis (Normal Health)




Source: Company report.

Exhibit 11: Idiopathic Pulmonary Fibrosis

The Need in Idiopathic Pulmonary Fibrosis

A Rare Chronic Progressive Pulmonary Disease with Abnormal Scarring of the Lungs Blocking the Movement of Oxygen into the Bloodstream



The complex block contains a diagram on the left showing a cross-section of a lung with a yellow arrow indicating oxygen flow and a blue arrow indicating CO₂ flow. The area between the lung and a red blood vessel is labeled 'SCARRING'. To the right, a list of statistics is presented: '~66 Age of onset¹', '50% 5/10 die within 2-3 years of diagnosis²', '20% 8/10 die within 5 years of diagnosis²', and '0% Survival without a lung transplant³'. Below these statistics, a pink banner contains the text: 'Current Treatments are Limited with Only 2 Approved Drugs', 'Significant side-effects, limited compliance and no impact on survival³', and 'Despite challenges, total 2022 sales were ~\$4.3 billion combined⁴'. On the far right, a photograph shows an elderly man coughing into a tissue.

~66 Age of onset¹

50% 5/10 die within 2-3 years of diagnosis²

20% 8/10 die within 5 years of diagnosis²

0% Survival without a lung transplant³

Current Treatments are Limited with Only 2 Approved Drugs
Significant side-effects, limited compliance and no impact on survival³
Despite challenges, total 2022 sales were ~\$4.3 billion combined⁴

Source: Company reports.

Exhibit 12: GRI-0621 For IPF Benefits

GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis

- Small molecule RAR- β dual agonist that inhibits the activity of human iNKT cells
- iNKT inhibition demonstrated fibrosis resolution in multiple animal models
- Established safety profile as an oral formulation
 - GRI-0621 is an oral formulation of an FDA-approved topical dermatology product, tazarotene
 - Prior late-stage studies of an oral formulation of tazarotene demonstrated favorable safety profile in ~1,700 subjects
- Extensive IP protection with issued medical use patents and market LOE through 2036

Source: Company reports.

Exhibit 13: GRI-0621 for IPF Phase 2 Clinical Trial

KEY INCLUSION CRITERIA

1. Men or women 40-85 yrs
2. Confirmed IPF diagnosis
3. FVC > 50% predicted
4. FEV1/FVC > 0.65
5. DLCOc > 30% predicted
6. Life expectancy of at least 12-months
7. Subjects on approved IPF therapy must remain on their current medication from Screening until the last study visit

Ongoing Phase 2 Study in IPF

PRIMARY & SECONDARY ENDPOINTS

Safety, tolerability and PK
Biomarkers change from baseline

To determine the PD activity of oral GRI-0621 as measured by inhibition of iNKT cell activation in blood after 6 & 12 weeks and from BAL after 12 weeks of treatment in a sub-study

EXPLORATORY ENDPOINTS

Effect of GRI-0621 on pulmonary function (FEV1, FVC and FEV1/FVC ratio) at baseline and after 6 and 12 weeks of treatment

Source: Company reports.

Exhibit 14: GRI-0803 For Systemic Lupus Erythematosus (SLE)

GRI-0803

Initial Focus on Systemic Lupus Erythematosus (SLE)

Novel activator of human type 2 NKT cells

Extensive IP protection with issued composition of matter and use patents and market LOE through 2038

GRI-0803 is a novel activator of human type 2 NKT cells in development for the treatment of autoimmune disorders, with an initial focus on systemic lupus erythematosus (SLE). Activation of type 2 NKT leads to a dendritic cell-mediated inhibition of iNKT cells. In our preclinical studies, type 2 NKT activating molecules, GRI-0803 and GRI-0124, were observed to inhibit both murine and human iNKT cells. Oral administration of these type 2 NKT activating molecules was observed to inhibit lupus nephritis and to significantly improve overall survival.

Key Highlights:

- Targets upstream in the inflammatory cascade providing potential for greater efficacy
- Oral administration in a spontaneous model of lupus nephritis demonstrated significant inhibition of pro-inflammatory cytokines, including IL-6 and IL-17; significant inhibition of autoantibodies; and improvement in overall and proteinuria-free survival

Advancing Toward the Clinic

IND-Enabling and Phase 1 Program to Advance in 2025

Steps Toward
IND Filing

- Validate bioanalytical methods
- Complete cGMP manufacturing
- Complete toxicology studies

Source: Company reports.

Exhibit 15: Systemic Lupus Erythematosus (SLE)

The Need in Systemic Lupus Erythematosus


The most common form of lupus, SLE, is an autoimmune disease in which the immune system attacks its own tissue and organs

<p>~160K PREVALENCE Confirmed as definite SLE¹</p>	<p>70% DIAGNOSIS Number of all lupus cases²</p>	<p>15 - 44 AGE RANGE Commonly affects women of childbearing age¹</p>
--	---	--

Current treatments are limited, consisting primarily of immunosuppressive therapies

Only 2 drugs approved for SLE in the past 50 years

1. <https://www.cdc.gov/lupus/facts.html>



Source: Company reports.

Exhibit 16: GRI Bio's Strategy (as of March 2024)

Our Strategy

Our goal is to become a leader in developing and commercializing therapeutics that target diseases with significant unmet needs. Our initial focus is on developing product candidates that target the activity of NKT cells and their role in driving dysregulated immune responses. Our strategy is focused on the following key components:

- **Efficiently advance the clinical development of GRI-0621 in IPF** . We intend to conduct a randomized double-blind placebo-controlled Phase 2a trial in approximately 36 patients with IPF with topline data expected in the second half of 2024. This orphan disease is therapeutically underserved, and we believe that GRI-0621 may have the ability to become the first true disease-modifying therapy for these patients. Assuming a positive result in this trial, we plan to initiate a Phase 2b trial that could support an application for conditional approval of GRI-0621 in the European Union (EU) and could have the potential to be regarded as a registrational trial in the United States.
- **Advance GRI-0803 through Phase 1a/1b studies initially targeting SLE** . Subject to IND clearance, we intend to evaluate GRI-0803 in a Phase 1a and 1b trial initially targeting SLE. We expect to file an IND with respect to this trial in the first half of 2024.
- **Leverage our understanding of iNKT and type 2 NKT cells in disease and continue evaluating GRI-0621, GRI-0803, and additional product candidates in subsequent indications** . We intend to expand our leadership as a company dedicated to developing therapies that directly target the biological processes driving dysregulated immune responses. We also intend to selectively pursue business development opportunities to expand our product portfolio and supporting technologies.
- **Continue to build a patient-focused company across a broad range of inflammatory, fibrotic and autoimmune diseases** . In building a patient-focused company to address the needs of patients, we will work with clinicians, patient advocacy groups, medical centers of excellence, and medical key opinion leaders to better understand the symptoms and consequences of these diseases, to expeditiously develop and provide better treatments to patients, and to increase awareness of these diseases.
- **Maximize the commercial value of our product candidates** . We have retained worldwide development and commercial rights for all our product candidates. We intend to commercialize any products in our portfolio for which we receive regulatory approvals in certain rare indications in the United States and the EU with a limited and targeted commercial team. We also intend to retain the flexibility to evaluate strategic collaborations and to seek partners to commercialize our products in other geographies and for our products in highly prevalent indications which require significant investment to build a commercial infrastructure.

Source: Company reports.

Exhibit 17: Q4 2024 Financial Report and Recent Highlights (as of March 17, 2025)

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF")

Interim data and topline data readouts from Phase 2a biomarker study expected in Q2 2025 and Q3 2025, respectively

Cash runway expected to fund operations into Q2 2025, including interim data readout from GRI-0621

LA JOLLA, CA, March 17, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, has reported its financial results for the fiscal year ended December 31, 2024 and today provided a corporate update.

"Over the last year, we made significant progress on the development of our lead program GRI-0621 for the treatment of IPF. We continue to make strides towards our anticipated interim data readout and topline data readout which remain on track for the second and third quarter of 2025, respectively. We remain confident that the data observed to date, and the additional data readouts anticipated this year, will position us to build momentum and drive value for shareholders in the near and long term," commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio.

Recent Highlights

- Presented positive preclinical data demonstrating its lead program GRI-0621 reduces important inflammatory and fibrotic drivers in IPF at the 8th Annual Antifibrotic Drug Development Summit; and
- Granted European patent covering GRI-0803 and the Company's library of 500+ proprietary compounds.

Source: Company reports.

Exhibit 18: Upcoming Milestones (as of March 17, 2025)

Expected GRI-0621 Upcoming Milestones

- Q2 2025: Report interim data from Phase 2a biomarker study
- Q3 2025: Report topline results from Phase 2a biomarker study

Source: Company reports.

Exhibit 19: GRI Bio, Inc. Stock Price (4-years since reverse merger)

Merger Announcement (with GRI Bio, Inc.) - 12/13/22

Merger Completion (to form GRI Bio, Inc.) - 4/21/23



*Reflects a 1:30 reverse stock split in April 2023.

*Reflects a 1:7 reverse stock split in January 2024.

*Reflects a 1:13 reverse stock split in June 2024.

*Reflects a 1:17 reverse stock split in February 2025.

Source: <https://bigcharts.marketwatch.com/>

Exhibit 20: Consensus Expectations (as of March 17, 2025)

	Revenue (mils)			EPS	
	2024E	2025E		2024E	2025E
Q1 Mar	\$0A	\$0.0E	Q1 Mar	\$(5.94)A	\$(0.24)E
Q2 Jun	\$0A		Q2 Jun	\$(4.92)A	
Q3 Sep	\$0A		Q3 Sep	\$(0.67)A	
Q4 Dec	\$0E		Q4 Dec	\$(0.32)E	
Total	\$0E	\$0E	Total	\$(2.83)E	\$(0.93)E

*Quarterly estimates may not add to annual estimates due to variations in contributing estimates and rounding.

*Reflects a 1:7 reverse stock split in January 2024.

*Reflects a 1:13 reverse stock split in June 2024.

*Reflects a 1:17 reverse stock split in February 2025.

Source: Company report, LSEG, and Ascendant Capital Markets estimates

FINANCIAL MODEL

GRI Bio, Inc.

Income Statement (\$ mils)	Mar-23	Jun-23	Sep-23	Dec-23	2023	Mar-24	Jun-24	Sep-24	Dec-24	2024	Mar-25	Jun-25	Sep-25	Dec-25	2025	Mar-26	Jun-26	Sep-26	Dec-26	2026
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1E	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Total Revenue	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Cost of Revenues	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Gross Profit	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Research & development	0.116	0.880	1.189	1.047	3.232	0.933	0.877	1.130	0.83	3.768	1.000	1.000	1.000	1.000	4.000	1.000	1.000	1.000	1.000	4.000
General & administrative	0.872	5.054	1.250	0.979	8.155	0.962	1.380	1.000	1.125	4.467	1.200	1.200	1.200	1.200	4.800	1.200	1.200	1.200	1.200	4.800
Restructuring and other					0.000					0.000					0.000					0.000
Total operating expenses	0.988	5.934	2.439	2.026	11.387	1.895	2.257	2.130	1.953	8.235	2.200	2.200	2.200	2.200	8.800	2.200	2.200	2.200	2.200	8.800
Operating income (loss)	(0.988)	(5.934)	(2.439)	(2.026)	(11.387)	(1.895)	(2.257)	(2.130)	(1.953)	(8.235)	(2.200)	(2.200)	(2.200)	(2.200)	(8.800)	(2.200)	(2.200)	(2.200)	(2.200)	(8.800)
Interest income (expense)	(1.162)	(0.934)	0.006	0.01	(2.082)	0.006	0.006	0.007	0.006	0.025	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Other income (expense)		0.122	0.296	0.014	0.432	0.002	0.001		(1.911)	(1.908)	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Income before income taxes	(2.150)	(6.746)	(2.137)	(2.004)	(13.037)	(1.887)	(2.250)	(2.123)	(3.858)	(10.118)	(2.200)	(2.200)	(2.200)	(2.200)	(8.800)	(2.200)	(2.200)	(2.200)	(2.200)	(8.800)
Income taxes					0.000					0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Net income (loss)	(2.150)	(6.746)	(2.137)	(2.004)	(13.037)	(1.887)	(2.250)	(2.123)	(3.858)	(10.118)	(2.200)	(2.200)	(2.200)	(2.200)	(8.800)	(2.200)	(2.200)	(2.200)	(2.200)	(8.800)
Nonrecurring/noncash adjustments		0.000		(0.001)	(0.001)					0.000					0.000					0.000
Net income (pro forma)	(2.150)	(6.746)	(2.137)	(2.005)	(13.038)	(1.887)	(2.250)	(2.123)	(3.858)	(10.118)	(2.200)	(2.200)	(2.200)	(2.200)	(8.800)	(2.200)	(2.200)	(2.200)	(2.200)	(8.800)
EBITDA																				
Shares, Basic	0.001	0.002	0.003	0.003	0.002	0.019	0.027	0.186	0.500	0.183	0.535	2.000	2.100	2.200	1.709	2.300	2.400	2.500	2.600	2.450
Shares, Diluted	0.001	0.002	0.003	0.003	0.002	0.019	0.027	0.186	0.500	0.183	0.535	2.000	2.100	2.200	1.709	2.300	2.400	2.500	2.600	2.450
EPS Basic (pro forma)	(\$3,323.01)	(\$4,069.36)	(\$801.54)	(\$587.67)	(\$6,242.56)	(\$101.04)	(\$83.56)	(\$11.42)	(\$7.72)	(\$55.21)	(\$4.11)	(\$1.10)	(\$1.05)	(\$1.00)	(\$5.15)	(\$0.96)	(\$0.92)	(\$0.88)	(\$0.85)	(\$3.59)
EPS Diluted (pro forma)	(\$3,323.01)	(\$4,069.36)	(\$801.54)	(\$587.67)	(\$6,242.56)	(\$101.04)	(\$83.56)	(\$11.42)	(\$7.72)	(\$55.21)	(\$4.11)	(\$1.10)	(\$1.05)	(\$1.00)	(\$5.15)	(\$0.96)	(\$0.92)	(\$0.88)	(\$0.85)	(\$3.59)
Margins																				
Gross margin																				
Research & development																				
General & administrative																				
Operating margin																				
Tax rate, GAAP																				
Net margin																				
Y/Y % change																				
Total Revenue																				
Gross margin																				
Research & development	93%	1392%	1787%	1645%	1236%	704%	0%	-5%	-21%	17%	7%	14%	-12%	21%	6%	0%	0%	0%	0%	0%
General & administrative	532%	3788%	916%	-39%	308%	10%	-73%	-20%	15%	-45%	25%	-13%	20%	7%	7%	0%	0%	0%	0%	0%
Operating income (loss)	399%	3040%	1211%	22%	409%	92%	-62%	-13%	-4%	-28%	16%	-3%	3%	13%	7%	0%	0%	0%	0%	0%
Net income (loss)	612%	2187%	509%	-12%	305%	-12%	-67%	-1%	93%	-22%	17%	-2%	4%	-43%	-13%	0%	0%	0%	0%	0%
EPS Diluted (pro forma)	506%	659%	32%	-85%	13%	-97%	-98%	-99%	-99%	-99%	-96%	-99%	-91%	-87%	-91%	-77%	-17%	-16%	-15%	-30%

Source: Company reports and Ascendant Capital Markets estimates.

Reflects a 1:7 reverse stock split in January 2024 Reflects a 1:13 reverse stock split in June 2024

Reflects a 1:17 reverse stock split in February 2025

GRI Bio, Inc.

Balance Sheet (\$ mils)	Jun-23	Sep-23	Dec-23	Mar-24	Jun-24	Sep-24	Dec-24	Mar-25	Jun-25	Sep-25	Dec-25	Mar-26	Jun-26	Sep-26	Dec-26
Fiscal Year End: December 31	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1E	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Assets															
Cash and cash equivalents	4.799	3.488	1.808	4.091	6.353	4.746	5.028	2.865	5.702	4.848	2.885	0.722	(1.441)	(3.804)	(5.767)
Short term investments								0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Deferred income taxes								0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Prepaid expenses and other	0.793	0.879	1.126	0.337	0.531	0.577	0.587	0.587	0.587	0.587	0.587	0.587	0.587	0.587	0.587
Total current assets	5.592	4.367	2.934	4.428	6.884	5.323	5.615	3.452	6.289	5.435	3.472	1.309	(0.854)	(3.217)	(5.180)
Property and equipment, net	0.009	0.009	0.008	0.007	0.006	0.005	0.004	0.004	0.004	0.004	0.004	0.004	0.004	0.004	0.004
Intangibles, net								0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Deferred income tax								0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Other	0.041	0.028	0.014	0.152	0.141	0.131	0.120	0.120	0.120	0.120	0.120	0.120	0.120	0.120	0.120
Total assets	5.642	4.404	2.956	4.587	7.031	5.459	5.739	3.576	6.413	5.559	3.596	1.433	(0.730)	(3.093)	(5.056)
Liabilities and stockholders' equity															
Accounts payable	0.307	0.988	1.410	0.637	1.236	1.137	0.897	0.897	0.897	0.897	0.897	0.897	0.897	0.897	0.897
Accrued expenses	1.193	1.143	1.270	0.999	0.935	0.531	0.691	0.691	0.691	2.000	2.200	2.200	2.200	2.000	2.200
Deferred income tax								0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Warrant liabilities	0.063	0.018	0.003	0.001				0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Other	0.041	0.028	0.014	0.043	0.045	0.047	0.048	0.048	0.048	0.048	0.048	0.048	0.048	0.048	0.048
<u>Short term debt</u>								0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Total current liabilities	1.604	2.177	2.697	1.680	2.216	1.715	1.636	1.636	1.636	2.945	3.145	3.145	3.145	2.945	3.145
Deferred income taxes								0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Warrant liabilities								0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Other long term liabilities				0.109	0.096	0.084	0.071	0.071	0.071	0.071	0.071	0.071	0.071	0.071	0.071
<u>Long term debt</u>								0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Total other liabilities	0.000	0.000	0.000	0.109	0.096	0.084	0.071	0.071	0.071	0.071	0.071	0.071	0.071	0.071	0.071
Preferred stock								0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Common stock								0.037	0.074	0.111	0.148	0.185	0.222	0.259	0.296
Additional paid-in capital	31.430	31.756	31.792	36.218	40.389	41.453	43.772	43.772	43.772	43.772	43.772	43.772	43.772	43.772	43.772
Retained earnings	(27.392)	(29.529)	(31.533)	(33.420)	(35.670)	(37.793)	(39.740)	(41.940)	(44.140)	(46.340)	(48.540)	(50.740)	(52.940)	(55.140)	(57.340)
Other								0.000	5.000	5.000	5.000	5.000	5.000	5.000	5.000
Accumulated other comprehensive income								0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Total stockholders' equity	4.038	2.227	0.259	2.798	4.719	3.660	4.032	1.869	4.706	2.543	0.380	(1.783)	(3.946)	(6.109)	(8.272)
Total stockholders' equity and liabilities	5.642	4.404	2.956	4.587	7.031	5.459	5.739	3.576	6.413	5.559	3.596	1.433	(0.730)	(3.093)	(5.056)

Balance Sheet Drivers

	Jun-23	Sep-23	Dec-23	Mar-24	Jun-24	Sep-24	Dec-24	Mar-25	Jun-25	Sep-25	Dec-25	Mar-26	Jun-26	Sep-26	Dec-26
Book & Cash Value (per share)	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1E	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Book Value per Share (diluted)	#####	\$835.30	\$75.91	\$149.82	\$175.26	\$19.69	\$8.06	\$3.49	\$2.35	\$1.21	\$0.17	-\$0.78	-\$1.64	-\$2.44	-\$3.18
Cash per Share (diluted)	#####	#####	\$529.93	\$219.05	\$235.94	\$25.53	\$10.06	\$5.35	\$2.85	\$2.31	\$1.31	\$0.31	-\$0.60	-\$1.52	-\$2.22
Net cash per Share (diluted)	#####	#####	\$529.93	\$219.05	\$235.94	\$25.53	\$10.06	\$5.35	\$2.85	\$2.31	\$1.31	\$0.31	-\$0.60	-\$1.52	-\$2.22

Source: Company reports and Ascendant Capital Markets estimates

GRI Bio, Inc.

Cash Flow Statement (\$ mils)	Mar-23	Jun-23	Sep-23	Dec-23	2023	Mar-24	Jun-24	Sep-24	Dec-24	2024	Mar-25	Jun-25	Sep-25	Dec-25	2025	Mar-26	Jun-26	Sep-26	Dec-26	2026
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1E	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Cash flow from operating activities																				
Net income	(2.150)	(6.746)	(2.137)	(2.004)	(13.037)	(1.887)	(2.250)	(2.122)	(1.948)	(8.207)	(2.200)	(2.200)	(2.200)	(2.200)	(8.800)	(2.200)	(2.200)	(2.200)	(2.200)	(8.800)
Depreciation	0.001	0.001	0.001	0.001	0.004	0.001	0.001	0.001	0.001	0.004					0.000					0.000
Amortization					0.000					0.000					0.000					0.000
Non-cash lease expense					0.000					0.000					0.000					0.000
Debt related amortization expen	1.161	0.943			2.104					0.000					0.000					0.000
Stock comp	0.013	0.013	0.326	0.036	0.388	0.037	0.037	0.037	0.037	0.148	0.037	0.037	0.037	0.037	0.148	0.037	0.037	0.037	0.037	0.148
Deferred income taxes					0.000					0.000					0.000					0.000
Change in fair value of warrant liability		0.063	(0.045)	(0.200)	(0.182)	(0.002)	(0.001)		0.010	(0.003)					0.000					0.000
Lease	0.012	0.014	0.013	0.014	0.053	0.014	(0.141)		0.012	(0.105)					0.000					0.000
Inventory reserve					0.000					0.000					0.000					0.000
Accrued interest					0.000					0.000					0.000					0.000
Writedowns and impairments					0.000					0.000					0.000					0.000
Other gains/losses					0.000					0.000					0.000					0.000
Other					0.000					0.000					0.000					0.000
Changes in operating assets and liabilities:																				
Prepaid expenses & other curre	0.028	(0.778)	(0.086)	0.289	(0.547)	0.564	(0.194)	(0.048)	(0.009)	0.313	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Income tax					0.000					0.000					0.000					0.000
Other assets					0.000					0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Accounts payable	0.408	3.771	0.681	(2.701)	2.159	(0.744)	0.344	0.253	(0.240)	(0.387)	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Accrued expenses	(0.036)	1.193	(0.051)	(0.981)	0.125	(0.172)	(0.078)	(0.389)	0.160	(0.479)	0.000	0.000	1.309	0.200	1.509	0.000	0.000	(0.200)	0.200	0.000
Deferred revenue					0.000					0.000					0.000					0.000
Other liabilities	(0.016)	(0.014)	(0.013)	(0.014)	(0.057)	(0.014)	0.141	(0.010)	(0.012)	0.105	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Net cash (used in) provided by	(0.579)	(1.540)	(1.311)	(5.560)	(8.990)	(2.203)	(2.141)	(2.268)	(6.612)	(8.611)	(2.163)	(2.163)	(0.854)	(1.963)	(7.143)	(2.163)	(2.163)	(2.363)	(1.963)	(8.652)
Cash flow from investing activities																				
Purchases of property and equipment		(0.008)			(0.008)					0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Purchases of short-term investments					0.000					0.000					0.000					0.000
Acquisitions					0.000					0.000					0.000					0.000
Other					0.000					0.000					0.000					0.000
Net cash used in investing acti	0.000	(0.008)	0.000	0.000	(0.008)	0.000														
Cash flow from financing activities																				
Issuance of debt	1.440	0.000	(1.250)		0.190					0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Repayment of debt	(0.195)				(0.195)					0.000					0.000					0.000
Issuance of stock	(0.215)	12.465	1.250		13.500	4.486	4.403	0.661	1.520	11.070	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Proceeds from stock option exercises		0.012			0.012				0.762	0.762					0.000					0.000
Other		(6.590)	0.000	3.880	(2.710)				(0.001)	(0.001)		5.000		5.000						0.000
Dividends and distributions					0.000					0.000					0.000					0.000
Cash provided by (used in) fina	1.030	5.887	0.000	3.880	10.797	4.486	4.403	0.661	2.281	11.831	0.000	5.000	0.000	0.000	5.000	0.000	0.000	0.000	0.000	0.000
Effect of exchange rate on cash					0.000					0.000					0.000					0.000
Net increase (decrease) in cash	0.451	4.339	(1.311)	(1.680)	1.799	2.283	2.262	(1.607)	(4.331)	3.220	(2.163)	2.837	(0.854)	(1.963)	(2.143)	(2.163)	(2.163)	(2.363)	(1.963)	(8.652)
Beginning cash and equivalents	0.009	0.460	4.799	3.488	0.009	1.808	4.091	6.353	4.746	1.808	5.028	2.865	5.702	4.848	5.028	2.885	0.722	(1.441)	(3.804)	2.885
Ending cash and equivalents	0.460	4.799	3.488	1.808	1.808	4.091	6.353	4.746	0.415	5.028	2.865	5.702	4.848	2.885	2.885	0.722	(1.441)	(3.804)	(5.767)	(5.767)

Source: Company reports and Ascendant Capital Markets estimates

ANALYST CERTIFICATION

Each analyst hereby certifies that the views expressed in this report reflect the analyst's personal views about the subject securities or issuers. Each analyst also certifies that no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The analyst who prepared this report is compensated based upon the overall profitability of Ascendant Capital Markets, LLC, which may, from time to time, include the provision of investment banking, financial advisory and consulting services. Compensation for research is based on effectiveness in generating new ideas for clients, performance of recommendations, accuracy of earnings estimates, and service to clients.

GRI Bio, Inc.

- Ascendant Capital Markets, LLC has received compensation for advisory or investment banking services from the company in the past 12 months.

IMPORTANT DISCLOSURES

This report has been distributed by Ascendant Capital Markets, LLC and is for the sole use of our clients. This report is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. This report contains information from various sources, including United States government publications, The Wall Street Journal and other periodicals, Yahoo! Finance and other sources, and is for informational purposes only and is not a recommendation to trade in the securities of the companies mentioned within the report. We seek to update our research and recommendations as appropriate, but the large majority of reports are published at irregular intervals as we consider appropriate and, in some cases, as constrained by industry regulations.

We may have a business relationship with companies covered in this report. Ascendant Capital Markets, LLC may make a market in the securities of the subject company. We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this report. This report is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any information in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to in this report may fluctuate.

Following are some general risks that can adversely impact future operational and financial performance and share price valuation: (1) industry fundamentals with respect to legislation, mandates, incentives, customer demand, or product pricing; (2) issues relating to competing companies or products; (3) unforeseen developments with respect to management, financial condition or accounting policies or practices; or (4) external factors that affect the interest rates, currency, the economy or major segments of the economy. Past performance is not a guide to future performance, future returns are not guaranteed, and loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Our report is disseminated primarily electronically, and, in some cases, in printed form. The information contained in this report is not incorporated into the contents of our website and should be read independently thereof. Copyright Ascendant Capital Markets, LLC. No part of this material may be copied, photocopied or duplicated by any means or redistributed without the prior written consent of Ascendant Capital Markets, LLC.

Risks & Considerations

Risks to attainment of our share price target include balance sheet/liquidity risks, failure of product candidates to demonstrate safety and efficacy in clinical trials, failure to gain regulatory approvals, ability to commercialize product, failure to obtain suitable reimbursement, competition, changing macroeconomic factors, investor sentiment for investing in biotech stocks, and changes in consumer or government priorities for healthcare.

Ascendant Capital Markets, LLC Rating System

BUY: We expect the stock to provide a total return of 15% or more within a 12-month period.

HOLD: We expect the stock to provide a total return of negative 15% to positive 15% within a 12-month period.

SELL: We expect the stock to have a negative total return of more than 15% within a 12-month period.

Total return is defined as price appreciation plus dividend yield.

Ascendant Capital Markets, LLC Distribution of Investment Ratings (as of April 11, 2025)

Rating	Count	Percent	Investment Banking Services Past 12 months	
			Count	Percent
Buy	52	98%	21	40%
Hold	0	0%	0	0%
Sell	1	2%	0	0%
Total	53	100%	21	40%

Other Important Disclosures

Our analysts use various valuation methodologies including discounted cash flow, price/earnings (P/E), enterprise value/EBITDAS, and P/E to growth rate, among others. Risks to our price targets include failure to achieve financial results, product risk, regulatory risk, general market conditions, and the risk of a change in economic conditions.

Dissemination of Research

Ascendant Capital Markets, LLC research is distributed electronically via the Thomson Reuters platforms, Bloomberg, Capital IQ and FactSet. Please contact your investment advisor or institutional salesperson for more information.

General Disclaimer

The information and opinions in this report were prepared by Ascendant Capital Markets, LLC. This information is not intended to be used as the primary basis of investment decisions and because of individual client objectives it should not be construed as advice designed to meet the particular investment needs of any investor. This material is for information purposes only and is not an offer or solicitation with respect to the purchase or sale of any security. The reader should assume that Ascendant Capital Markets, LLC may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers discussed herein. The opinions, estimates, and projections contained in this report are those of Ascendant Capital Markets, LLC as of the date of this report and are subject to change without notice. Ascendant Capital Markets, LLC endeavors to ensure that the contents have been compiled or derived from sources that we believe are reliable and contain information and opinions that are accurate and complete. However, Ascendant Capital Markets, LLC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein, and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to Ascendant Capital Markets, LLC, or its affiliates that is not reflected in this report. This report is not to be construed as an offer or solicitation to buy or sell any security.

Additional Disclosures

Ascendant Capital Markets, LLC is a broker-dealer registered with the United States Securities and Exchange Commission (SEC) and a member of the FINRA and SIPC. Ascendant Capital Markets, LLC is not a Registered Investment Advisor nor is it an investment advisor registered with the Securities and Exchange Commission or with the securities regulators of any state, and at the present time is not eligible to file for federal registration.